IReC-Bio and IReC Registry

Head Cancer Neck Clinical Trial

— IReC-Bio  

Official title:

Protocol for The International Centre for Recurrent Head and Neck Cancer (IReC) Tissue Biobank and Data Registry

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05885490
• Other study ID #: 5604
• Status: Not yet recruiting
• Start date: July 2024
• Est. completion date: December 2050

Study information

• Verified date: May 2024
• Source: Royal Marsden NHS Foundation Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

IReC is the world's first centre for recurrent head and neck cancers. We have the ambitious aim to create a centre of international excellence and set international standards in the curative treatment of recurrent head and neck cancers.

One of IReC's key objectives is to develop a national research tissue bank to support laboratory and translational research. The cornerstone of translational research is a well-annotated biobank of cancer samples to explore and validate key research findings.

The purpose of IReC-Bio is to support research into recurrent head and neck cancers. A central repository for the rarer recurrent cancers will allow the concentration of cases required in order to support translational research programmes. The overall aim is to facilitate research into understanding disease biology, identifying potentially curative treatments, and allow detailed investigations into the relationships between clinical, pathological and molecular characteristics and clinical outcomes.

Combining the IReC Registry and Biobank gives us a comprehensive data and sample set which has never been created before for recurrent head and neck cancer. The aim is to have a national, and in the future international, resource of the study of recurrent head and neck cancer on a molecular and clinical level to support novel ways of treating rHNC.

Description:

There are currently only a limited number of proven treatments for use in cancers of the head and neck, and a better understanding of the biology of different HNCs could lead to improved therapies. Although many patients with head and neck cancer can be offered potentially curative treatment, we do not understand why some people are cured and others are not. There has been an explosion in molecular research in many cancers, but this remains an understudied area in head and neck cancer. There are currently no treatments available to patients with head and neck cancer based on molecular characteristics.

The purpose of IReC-BIO is to support research into rHNCs. A central repository for the rarer recurrent cancers will allow the concentration of cases required in order to support translational research programmes. The overall aim is to facilitate research into understanding disease biology, identifying potentially curative treatments, and allow detailed investigations into the relationships between clinical, pathological and molecular characteristics and clinical outcomes.

Cancer registries store large quantities of data from defined cancer populations. Registry aims vary, but include analysing cancer trends over time and supplying data for research studies5-7. The NCDB and SEER are extensively studied registries, producing >200 publications per year6. Both provide a broad overview of all major cancers; however, they have notable datapoint gaps, in particular, recurrence and patient reported outcome measures (PROMs).

Establishing a cancer registry necessitates a balance of clinical, informatic, and financial influences. Cancer registry development is subject to numerous pitfalls, ranging from excessive datapoints to inadequate quality assurance7. These can be mitigated through adherence to best practice recommendations, for example the NAACCR and ENCR, which provide guidelines that standardise registry datasets8,9. However, not all recommendations are practical across all cancer diagnoses. In particular, rHNC requires a tailored approach to document the treatment and functional implications unique to this cohort, necessitating development of a registry specific to this disease.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 10000000
• Est. completion date: December 2050
• Est. primary completion date: December 2050
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Aged over 18 at time of diagnosis.

• Confirmed clinical, radiological, and/ or histological diagnosis of residual, recurrent, or new primary malignant head and neck cancer arising from the nasopharynx, oropharynx, oral cavity, larynx, hypopharynx, sinonasal cavities, major salivary glands and thyroid gland.

• Any mucosal, salivary gland, and thyroid histological subtype

• Ability to give informed consent.

• Details of clinical follow-up available

For IReC-BIO only:

• FFPE blocks(s) or fresh frozen tumour tissue available for collection

• Two or more tumour-containing blocks available from the same specimen

For QoL Questionnaires only:

• Patients who have received a diagnosis of rHNC no earlier than 6 weeks prior to study entry

Exclusion Criteria:

• Recurrent cutaneous (e.g., SCC, melanoma), sarcomatous, and lymphatic or haematological (e.g. lymphoma) malignancies of the head and neck

For IReC-BIO only:

• FFPE tumour samples contain insufficient tumour sample for analysis.

• Insufficient clinical details available

For QoL Questionnaires only:

• Patients who have received a diagnosis of rHNC more than 6 weeks prior to study entry

Related Conditions & MeSH terms

• Head and Neck Neoplasms
• Head Cancer Neck

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Royal Marsden NHS Foundation Trust

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Define the 2 year overall survival rates in all patients with rHNC	2-year overall survival from date of diagnosis	2 years
Secondary	Define the 2-year disease-free (DFS), disease-specific (DSS), and local recurrence free survival (LRFS) rates in all patients with rHNC.	2 year disease free survival, disease specific and local recurrence free survival rates in all patients with rHNC	2 years
Secondary	Define long-term functional outcomes after diagnosis of rHNC using gastrostomy and tracheostomy use as a surrogate marker up to 2 years after diagnosis with rHNC	1 and 2-year gastrostomy and tracheostomy status from date of diagnosis	2 years
Secondary	Assess swallow with Performance Status Scale for head and neck cancer patients (PSS-HN) scores up to 2 years after diagnosis of rHNC.	Entry, 6, 12 and 24-month PSS-HN NOD scores	2 years